An Open-label, Multicenter Study To Evaluate The Pharmacokinetics Of Single And Multiple Intravenous Doses Of Pantoprazole In Two Age Cohorts Of Hospitalized Pediatric Subjects 1 To 16 Years Of Age Who Are Candidates For Acid Suppression Therapy
Phase of Trial: Phase IV
Latest Information Update: 12 Oct 2017
At a glance
- Drugs Pantoprazole (Primary)
- Indications Gastro-oesophageal reflux
- Focus Pharmacokinetics
- Sponsors Pfizer
- 13 Jul 2017 Planned End Date changed from 20 Feb 2020 to 16 Mar 2020.
- 13 Jul 2017 Planned primary completion date changed from 23 Jan 2020 to 17 Feb 2020.
- 10 Jun 2017 Biomarkers information updated